Protease Assays
Our protease assay panel provides a platform for profiling and screening new protease inhibitors against all major classes of proteases, such as serine proteases, cysteine proteases, threonine proteases, aspartic proteases, glutamic proteases, and metalloproteases.
In the human genome, there are around 500 putative proteases. Proteases play a role in physiological processes by managing complicated proteolytic activities. Proteases are targeted successfully for the treatment of virus infections such as HIV and Hepatitis C. Inhibitors have been approved for the treatment of hypertension (ACE inhibitors), diabetes (DPP-IV inhibitor), and to prevent blood clots (Factor Xa inhibitors). Studies are underway for the treatment of Alzheimer’s, COVID-19, and cancer.
Reaction Biology has developed the largest protease assay panel for protease screening to ensure the most comprehensive selectivity data. Our protease assays are based on the cleavage of fluorogenic peptide substrates for quantification of the proteolytic activity of proteases enabling the screening of direct and allosteric inhibitors.
Protease panel profiling is a valuable tool to determine the selectivity of a new protease inhibitor and detect off-target effects supporting the creation of safe drug candidates.
- Fluorescence-based protease activity assay
- Low and large-scale protease screening, as well as high-throughput screening options, are available
- Full protease panel protease profiling is performed on a monthly basis
- Discover our new COVID-19-related protease assays
